Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Suzhou Genhouse Bio Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
The First Affiliated Hospital of Dalian Medical University
NGM Biopharmaceuticals, Inc
Wellmarker Bio
R-Pharm
AO GENERIUM
Centre Hospitalier Universitaire Vaudois
Zhejiang University
Palobiofarma SL
TopAlliance Biosciences
Affiliated Hospital of Jiangnan University
Aurigene Discovery Technologies Limited
Fudan University
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Karolinska University Hospital
Multitude Therapeutics Inc.
Centre Georges Francois Leclerc
Lebanese University
Avistone Biotechnology Co., Ltd.
Shanghai Henlius Biotech
Biocad
Second Affiliated Hospital of Guangzhou Medical University
Shandong Cancer Hospital and Institute
BGI, China
NovalGen Ltd.
Jemincare
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Fox Chase Cancer Center
University of Kansas Medical Center
Center Trials & Treatment Europe
Guangzhou Institute of Respiratory Disease
BGI, China
Qilu Pharmaceutical Co., Ltd.
Qianfoshan Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ascentage Pharma Group Inc.
Provectus Pharmaceuticals
Wellmarker Bio
Revolution Medicines, Inc.
Tianjin Medical University Cancer Institute and Hospital
Imperial College London
The First Affiliated Hospital of Bengbu Medical University
Tianjin Medical University Cancer Institute and Hospital
Silverback Therapeutics
Betta Pharmaceuticals Co., Ltd.
University of Tennessee
Lee's Pharmaceutical Limited